Baxter Is Still Undervalued

Filed under: Baxter Intl (BAX), Stocks to Buy

Baxter International (BAX), which I first wrote about on March 13, 2009 at a price of $51.16, still looks promising, for the following reasons.



Look for Baxter's 2010 revenue to increase 8-11%, propelled by sales rises in all business segments. Moreover, versatility remains Baxter's key. Baxter makes a variety of medical products across three divisions, including drugs and vaccines, dialysis equipment, and IV supplies. Demand for recombinants, plasma proteins, and antibody therapies in its bioscience unit should be especially strong.

Continue reading Baxter Is Still Undervalued

Baxter Is Still Undervalued originally appeared on BloggingStocks on Tue, 23 Mar 2010 17:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Full story at http://www.pheedcontent.com/click.phdo?i=ac92e7bce77d30e467ee8326e8a7f02e